Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 9/2017

01-09-2017 | Original Article

Vaccination in oncology practice and predictors

Authors: Ali Alkan, Ebru Karcı, Arzu Yaşar, Gülseren Tuncay, Elif Berna Köksoy, Muslih Ürün, Filiz Çay Şenler, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut, Yüksel Ürün

Published in: Supportive Care in Cancer | Issue 9/2017

Login to get access

Abstract

Purpose

Despite, vaccination is a highly effective and widely recommended for prevention of certain infections, vaccination coverage is very low. The purposes of this study were to evaluate the attitudes of medical oncologists towards vaccination and to identify predictors of intention to recommend vaccination in patients with cancer.

Methods

A structured questionnaire is formed to evaluate the daily practice of vaccination. Turkish medical oncologists were invited to this study via email, SMS, or phone call. Questionnaire was filled out and the data were stored in an online survey platform.

Results

Two hundred seventy-three medical oncologists participated in the survey. Influenza, Pneumococcus, and hepatitis B were the most commonly recommended vaccines (87.1, 72.8, 67.0%, respectively). Patients with lung cancer, lymphoma and breast cancer were the main malignancies that medical oncologists suggest vaccination (68.1, 68.1, 24.6%, respectively). The most common times for vaccination were during remission/follow-up period (68.4%) or before beginning chemotherapy (64.1%). Only 23.4% of the physicians thought that their recommendation for vaccination was efficient and adequate. Lack of time and lack of knowledge or experience about vaccination are the most common limitations. There is a positive correlation between experience in the field and evaluating patients for vaccination (r = 0.390, p < 0.001); on the other hand, there is negative correlation between number of patients seen per day and evaluating patients for vaccination (r = −0.080, p = 0.18). Experience with autologous or allogeneic bone marrow transplant patients is related with more tendency to evaluate patients for vaccination (p < 0.001).

Conclusions

Degree of experience in oncology especially in bone marrow transplant units and total number of patients seen per day are important predictors of vaccination practice in oncology. The frequency of recommendation increases with degree of experience, knowledge, and visit time per patient.
Appendix
Available only for authorised users
Literature
1.
Couch RB, Englund JA, Whimbey E (1997) Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 102(3A):2–9 discussion 25-6CrossRefPubMed
2.
Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, Group S (2010) Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect 138(12):1804–1810CrossRefPubMed
3.
Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M (2013) Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 10:CD008983
4.
Wumkes ML, van der Velden AM, van der Velden AW, Stouthard JM, Nijziel MR, Westerman M et al (2013) Influenza vaccination coverage in patients treated with chemotherapy: current clinical practice. Neth J Med 71(9):472–477PubMed
5.
Xu Y, Methuku N, Coimbatore P, Fitzgerald T, Huang Y, Xiao YY et al (2012) Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer. Oncologist 17(1):125–134CrossRefPubMedPubMedCentral
6.
Chiou WY, Hung SK, Lai CL, Lin HY, Su YC, Chen YC et al (2015) Effect of 23-Valent pneumococcal polysaccharide vaccine inoculated during anti-cancer treatment period in elderly lung cancer patients on community-acquired pneumonia hospitalization: a nationwide population-based cohort study. Medicine (Baltimore) 94(26):e1022CrossRef
7.
Urun Y, Akbulut H, Demirkazik A, Senler FC, Utkan G, Onur H et al (2013) Perception about influenza and pneumococcal vaccines and vaccination coverage among patients with malignancies and their family members. Journal of Buon 18(2):511–515PubMed
8.
Loulergue P, Mir O, Alexandre J, Ropert S, Goldwasser F, Launay O (2008) Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 19(9):1658CrossRefPubMed
9.
Lachenal F, Sebban C, Duruisseaux M, Biron P, Blay JY, Ghesquieres H (2010) Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center. Bull Cancer 97(4):E33–E36PubMed
10.
Hibberd PL, Rubin RH (1990) Approach to immunization in the immunosuppressed host. Infect Dis Clin N Am 4(1):123–142
11.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M et al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58(3):309–318CrossRefPubMed
12.
National Center for I, Respiratory D (2011) General recommendations on immunization—recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 60(2):1–64
13.
14.
15.
16.
Mackay HJ, McGee J, Villa D, Gubbay JB, Tinker LM, Shi L et al (2011) Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol 50(3):212–216CrossRefPubMed
17.
Rodriguez-Rieiro C, Dominguez-Berjon MF, Esteban-Vasallodominguez-Berjon MD, Cuadrado AR, Carrasco-Garrido P, Jimenez-Garcia R (2011) Coverage and predictors of influenza vaccine uptake among adults aged 16 to 59 years suffering from a chronic condition in Madrid, Spain. Hum Vaccin 7(5):557–562CrossRefPubMed
18.
Ring A, Marx G, Steer C, Harper P (2002) Influenza vaccination and chemotherapy: a shot in the dark? Support Care Cancer 10(6):462–465CrossRefPubMed
19.
Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, Elting LS (2005) Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 104(3):618–628CrossRefPubMed
20.
Poeppl W, Lagler H, Raderer M, Sperr WR, Zielinski C, Herkner H et al (2015) Influenza vaccination perception and coverage among patients with malignant disease. Vaccine 33(14):1682–1687CrossRefPubMed
21.
Vinograd I, Baslo R, Eliakim-Raz N, Farbman L, Taha A, Sakhnini A et al (2014) Factors associated with influenza vaccination among adult cancer patients: a case-control study. Clin Microbiol Infect 20(9):899–905CrossRefPubMed
22.
Akin S, Dizdar O, Ozisik L, Tanriover M, KAmisli S, Erman M et al (2016) Vaccination attitudes among patients with cancer receiving chemotherapy. International Journal of Hematology and Oncology 26:1–6CrossRef
23.
Romani MH, Musharrafieh UM, Lakkis NA, Hamadeh GN (2011) Family physicians beliefs and attitudes regarding adult pneumococcal and influenza immunization in Lebanon. Fam Pract 28(6):632–637CrossRefPubMed
24.
Ariza-Heredia EJ, Gulbis AM, Stolar KR, Kebriaei P, Shah DP, McConn KK et al (2014) Vaccination guidelines after hematopoietic stem cell transplantation: practitioners’ knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis 16(6):878–886CrossRefPubMed
Metadata
Title
Vaccination in oncology practice and predictors
Authors
Ali Alkan
Ebru Karcı
Arzu Yaşar
Gülseren Tuncay
Elif Berna Köksoy
Muslih Ürün
Filiz Çay Şenler
Ahmet Demirkazık
Güngör Utkan
Hakan Akbulut
Yüksel Ürün
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3675-y

Other articles of this Issue 9/2017

Supportive Care in Cancer 9/2017 Go to the issue

Original Article

Voice rehabilitation after laryngeal cancer: Associated effects on psychological well-being

Review Article

Influential factors on treatment decision making among patients with colorectal cancer: A scoping review

Review Article

Biomarkers and non-invasive tests for gastrointestinal mucositis

Original Article

Mapping French people and health professionals’ positions regarding the circumstances of morphine use to relieve cancer pain

Original Article

Benefits and risks of a percutaneous endoscopic gastrostomy (PEG) for decompression in patients with malignant gastrointestinal obstruction

Original Article

Physiotherapy programme reduces fatigue in patients with advanced cancer receiving palliative care: randomized controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits